drugset / Trial / NCT00192179
A Phase II, Trial to Assess the Safety and Tolerability of Influenza Virus Vaccine, CAIV-T in Healthy Children and Adolescents Ages 6 to Less Than 18 Years.
Phase 2
Completed
240 enrolled
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer · collab
RandomizedParallel-groupQuadruple-blindPrevention
Summary
A safety study to compare, over a 7 day period, the fever rates following one dose of either Influenza Virus Vaccine or placebo administered outside the influenza season to healthy children and adolescents aged 6 to less than 18 years.
Timeline
- Start
- 2003-06
- Primary completion
- 2003-07
- Completion
- 2003-07
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | FluMist | Vaccine | 0.2 ml | Intranasal |